Prostate Cancer: A worldwide approach

Monday, July	11 th , 2022	
18:30 - 19:00 GMT-4	Who, when and how to biopsy. Current state of the art on prostate cancer detection	Mark Emberton, MD
19:00 - 19:30 GMT-4	What is what An update on prostate cancer pathology	Andrés Matoso, MD
19:30 - 20:00 GMT-4	MRI, microultrasound and everything you need to know about active surveillance on 2022	Laurence Klotz, MD
20:00 - 21:00 GMT-4	Clinical case	
Tuesday, July	12 th , 2022	
18:30 - 19:00 GMT-4	Predicting prostate cancer behavior, are we there yet? Biomarkers and genomics	Levin Martínez, MD
19:00 - 19:30 GMT-4	Current role of focal therapy in the shifting paradigm of prostate cancer treatment	Rafael Sánchez-Salas, MD
19:30 - 20:00 GMT-4	Bayer symposium	
20:00 - 21:00 GMT-4	Clinical case	
Wednesday, Ju	uly 13 th , 2022	
18:30 - 19:00 GMT-4	State of the art robotic radical prostatectomy, decreasing collateral damage	Rafael Coelho, MD
19:00 - 19:30 GMT-4	High risk patient, the surgeons view	Stephen Boorjian, MD
19:30 - 20:00 GMT-4	High risk patient, the radiotherapist view	Alejandro Berlín, MD
20:00 - 21:00 GMT-4	Clinical case	
Thursday, July	14 th , 2022	
18:30 - 19:00 GMT-4	Clinical N1, pathological N1 and all you need to know about locally advanced disease	Karim Touijer, MD
19:00 - 19:30 GMT-4	Biochemical recurrence, salvage radiotherapy and MDT	Brian Chapin, MD
19:30 - 20:00 GMT-4	Symposium	
20:00 - 21:00 GMT-4	Test predictor de metástasis	Javier Cerda, PhD
Friday, July 15	th , 2022	
18:30 - 19:00 GMT-4	MHSPC, is there an ideal sequence to start with?	Neal Shore, MD
19:00 - 19:30 GMT-4	MCRPC best standard of care and new horizons	Alicia Morgans, MD
19:30 - 20:00 GMT-4	All you need to know about new targeted therapies and PSMA	Michael Morris, MD
20:00 - 21:00 GMT-4	Clinical case	